EBMT 2024 | Emerging therapies for EBV-driven PTLD & insights into the ALLELE trial

Susan Prockop • 16 Apr 2024

EBMT 2024

General Tabelecleucel

ALLELE

Susan Prockop, MD, Boston Children’s Hospital, Dana-Farber Cancer Institute, Boston, MA, discusses the emerging efficacy of adoptive T-cell therapies for patients with Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease (PTLD). Dr Prockop details the Phase III ALLELE trial (NCT03394365), in which tabelecleucel elicited responses in over half of the treated patients with PTLD, including durable partial responses. In regard to treatment tolerability, adverse events were manageable with minimal treatment-emergent adverse events (TEAEs) related to therapy. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Support for the conduct of clinical trials through Boston Children’s Hospital from AlloVir, Atara, and Jasper. Inventor of IP related to development of third party viral specific T cells with all rights assigned to Memorial Sloan Kettering Cancer Center.
Speaker’s Honoraria: Pierre Fabre, Regeneron,
Consulting: CellEvolve, Century Therapeutics.